Amneal Reports Q3 2026 Results and Raises Full-Year Guidance
Amneal reported third-quarter revenue of $863 million, up 10% year over year; adjusted EBITDA rose 30% to $207 million and adjusted diluted EPS increased 53% to $0.26. It raised full-year 2026 guidance for revenue, adjusted EBITDA and adjusted diluted EPS.
Amneal Pharmaceuticals reported third-quarter 2026 net revenue of $863 million, representing a 10% increase compared to the same period in 2025. Adjusted EBITDA rose 30% to $207 million, while adjusted diluted earnings per share reached $0.26, a 53% increase year-over-year. The company attributed this performance to growth in its Specialty and Affordable Medicines segments, supported by new product launches including biosimilars and injectables. Following these results, management raised its full-year 2026 guidance for net revenue, adjusted EBITDA, and adjusted diluted EPS.
The company also noted that the integration of the Kashiv acquisition is proceeding as planned.